Sign up Australia
Proactive Investors - Run By Investors For Investors

Loxo Oncology shares soar on rosy data from Phase 1 cancer drug trial

Loxo 292 is meant for cancer patients with faulty RET genes where two genes have become fused together
Cancer headline in a newspaper
Loxo Oncology's shares are trading sharply higher in morning trade

Shares of Loxo Oncology Inc. (NASDAQ: LOXO), a biopharmaceutical company, soared Thursday after the cancer specialist revealed that its drug LOXO-292 shrunk tumors in as many as 70% of cancer patients who took part in an ongoing Phase 1 clinical trial.

In response to the news, investors sent up Loxo Oncology shares by 21% to US$168.70.

Stephen Willey, an analyst with Stifel, also raised his price target on the company's stock to US$190, arguing that the potency of LOXO-292 sets Loxo Oncology apart from its competitors who produce less-effective RET inhibitors.

LOXO-292, which addresses RET gene mutated cancers, was handled well by patients with late-stage cancers who had exhausted other available treatments.

The medicine is meant for cancer patients with faulty RET genes where two genes have become fused together, which fuels cancer growth.

In cancer patients with fused RET genes, roughly 69% of those who were assessed in Loxo's study saw tumors shrink, regardless of the type of cancer, and the tumors were reduced by as much as 67% in size.

A short analysis of preliminary data from its ongoing Phase 1 clinical trial for LOXO-292 was unveiled ahead of a presentation next month at the American Society of Clinical Oncology’s Annual meeting to be held from June 1-5 in Chicago.


View full LOXO profile View Profile

Loxo Oncology Timeline

Related Articles

Picture of Malaysian city
May 09 2018
The group’s ability to provide benefits to the retail sector was demonstrated in 2017.
Enertopia Corp's partner GWT upbeat on potential of lithium recovery tests
October 26 2017
The feedstock used in the tests comes from the group's Clayton valley project in Nevada
picture of oilfield
March 14 2018
Svetlana Mendesh, Chief Financial Officer, said 2016 results were in line with its projections and local market trends.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use